

Dr. Reddy's launches generic semaglutide injection in Canada, first approval in a G7 market

The launch follows Health Canada's Notice of Compliance on April 28, making Dr. Reddy's among the first companies to introduce a generic semaglutide injection in Canada.



Hyderabad: Dr. Reddy's Laboratories has launched its generic semaglutide injection in Canada, becoming among the first companies to introduce the therapy in the market after

receiving a Notice of Compliance (NOC) from Health Canada on April 28, 2026.

Canada has become the first G7 nation to grant market authorization for a generic version of semaglutide injection, marking a significant milestone for the GLP-1 therapy segment. The launch reflects Dr. Reddy's readiness to rapidly bring the treatment to patients following regulatory approval.

In Canada, the once-weekly semaglutide injection is indicated for adults with Type 2 Diabetes to improve glycaemic control alongside diet and exercise. The drug is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering semaglutide at a concentration of 1.34 mg/ml. The 2 mg pen provides 0.25 mg or 0.5 mg doses, while the 4 mg pen delivers 1 mg per injection.

Commenting on the launch, Erez Israeli, Chief Executive Officer, Dr. Reddy's Laboratories, informed that the company was pleased to introduce its generic semaglutide injection within days of receiving approval from Health Canada.

“The milestone highlights our readiness to serve Canadian patients, supported by our deep expertise in complex drug and peptide development. With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality and affordable GLP-1 therapies closer to patients,” Israeli said.

He added that the Canada launch builds on the company's recent introduction of semaglutide in India under the brand Obeda, noting that GLP-1 therapies remain a key strategic focus for the company as it works to expand access across global markets.

Semaglutide injection is prescribed for improving glycaemic control in adults with type 2 diabetes in combination with diet and exercise. It may be used when metformin is contraindicated or not tolerated, or alongside other treatments such as sulfonylureas, SGLT2 inhibitors, or basal insulin when adequate glycaemic control is not achieved.

The therapy is not indicated for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, and it has not been studied in combination with prandial insulin.

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/dr-reddys-launches-generic-semaglutide-injection-in-canada-first-approval-in-a-g7-market/131132499>